Sunitinib Does Not Accelerate Tumor Growth Post-Therapy
In a new study, researchers show that the TKI sunitinib, FDA-approved for advanced renal cell carcinoma, does not result in accelerated growth of kidney tumors after discontinuing treatment.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology